Inside the clean rooms where artificial intelligence (AI) infrastructure is born, a material bottleneck is quietly slowing down the future. Legacy photonics rely on indium phosphide, a substrate that's notoriously difficult to scale and prone to breaking. Aeluma, Inc. NASDAQ:ALMU has spent years developing a workaround. By integrating high-performance materials directly onto standard silicon and gallium arsenide wafers, it is attempting to solve the supply chain crisis for data center interconnects. The company is currently pivoting from a niche government contractor to a commercial chip supplier for the $1.8 trillion AI data center market.
Potential Bull Cases
1. The AI Infrastructure Explosion Creates a Massive Market for High-Volume Photonics
Data center capital investment is projected to reach $1.8 trillion by 2030, and photonics should capture 10% to 15% of that spending. This surge is driven by the need for faster interconnects to link thousands of graphics processing units in AI clusters. Aeluma's Lynx and Quasar product families are designed to fill this gap. Management is targeting a market that legacy suppliers can't fully serve due to raw material shortages. Because Aeluma uses non-indium phosphide substrates, it can theoretically manufacture chips at a scale that dwarfs traditional competitors. If it captures just a fraction of this build-out, the company moves from a research start-up to a central player in global compute infrastructure.
2. Proprietary Non-Indium Phosphide Technology Provides a Structural Cost and Scale Advantage
Aeluma holds a unique position as the first company to offer quantum dot lasers using the industry-standard metal-organic chemical vapor deposition production method. Traditional photonics relies on specialty wafers that are small and expensive. In contrast, Aeluma integrates these materials onto 6-inch and 8-inch wafers, with a roadmap to 12-inch silicon. This approach allows the company to use existing microelectronics factories rather than building costly new ones. This strategy aims to meet the volume requirements of the massive AI build-out that legacy materials simply can't satisfy. By moving to larger substrates, Aeluma can produce more chips per wafer at a lower unit cost.
3. Strategic Partnerships With Sumitomo and Tower Semiconductor De-Risk the Path to Volume
Semiconductor companies often fail during the transition from the lab to the factory floor, but Aeluma is leveraging a capital-light partnership model. It recently executed a strategic agreement with Sumitomo Chemical Advanced Technologies to increase wafer capacity. This deal allows Aeluma to run its proprietary processes on Sumitomo's existing tools, providing an immediate boost to manufacturing readiness without a massive upfront investment. Combined with its relationship with Tower Semiconductor, the company has a clear path to qualifying its products for marquee customers. These partnerships turn Aeluma's intellectual property into a scalable product line, shifting the investment thesis from a laboratory experiment to a legitimate manufacturing play with global reach.
4. The $30 Million CHIPS Funding Validates the Technology and Provides Non-Dilutive Capital
The U.S. Department of Commerce recently selected Aeluma for a $30 million letter of intent under the CHIPS R&D Office. This award supports Aeluma's commercial roadmap, unlike typical government grants, which come with rigid technical metrics. This funding is specifically aimed at accelerating photonics for AI and advanced computing. CFO Christopher Stewart noted that the government will likely take an equity stake rather than treating the funds as revenue. This provides a massive technical validation from the highest levels of government and provides the cash needed to scale operations. It gives the company the financial muscle to compete with larger incumbents while keeping the focus on commercialization rather than research.
5. A $56 Million Cash Pile Provides a Massive Runway for Commercial Inflection
Aeluma ended fiscal 2026 with a robust balance sheet featuring $56.0 million in cash and cash equivalents. This is a dramatic increase from the $3.6 million it held the previous year. The company successfully raised $20.1 million through an at-the-market offering at an average price of $24.87, showing strong institutional appetite for the stock. This capital covers the planned $10 million to $12 million in capital expenditures for fiscal 2027 while leaving years of operating cushion. With zero debt and a significant cash reserve, the company is not forced to chase dilutive financing or high-interest loans. It has the luxury of time to perfect its commercial products and win long-term customer contracts.
Potential Bear Cases
1. Revenue Remains Stagnant and Almost Entirely Dependent on Government R&D Contracts
Despite the bullish narrative around AI, Aeluma's top line has not yet moved into the commercial phase. Revenue for fiscal 2026 was $4.5 million, which was actually a slight decrease from the $4.7 million reported in fiscal 2025. Nearly all of this money comes from government R&D programs with NASA and the U.S. Navy. Management expects only $2.3 million in booked government revenue for fiscal 2027. This award supports Aeluma's own commercial roadmap, unlike typical government grants that come with rigid technical metrics. While there are ongoing negotiations for commercial non-recurring engineering deals, they haven't turned into reported revenue yet. Investors are paying a premium for a commercial future that currently exists only on paper.
2. Operating Losses Are Accelerating as the Company Ramps up Spending Before Commercial Sales
Aeluma's burn rate is increasing rapidly as it tries to build out its manufacturing capacity. The net loss for fiscal 2026 reached $9.2 million, more than triple the $3.0 million loss from the prior year. Adjusted EBITDA also swung from a positive $186,000 in fiscal 2025 to a loss of $5.2 million in 2026. This spending is driven by a headcount that doubled to 30 people and a planned capital expenditure of up to $12 million in the coming year. If commercial customers delay their orders or if the product qualification takes longer than expected, the company will burn through its cash reserves faster than the market currently anticipates.
3. Insider Selling and Lowered Price Targets Suggest a More Difficult Path Ahead
Significant insider selling can signal that management sees the stock as fully valued. On Sept. 21, 2026, CEO Jonathan Klamkin sold 100,000 shares for $1.3 million. This sale happened even as the company touted its transition to commercialization. Meanwhile, Freedom Broker lowered its price target for the stock from $30 to $25. While the firm maintained a buy rating, the reduction suggests that even the company's supporters see a lower ceiling for the stock in the near term. When the CEO takes significant profits off the table and analysts rein in their expectations, it creates a headwind for the stock that technical updates may struggle to overcome.
The Moneyball Verdict: 47 out of 100
Our proprietary Moneyball scoring system assigns Aeluma an overall Superscore of 47 out of 100, placing it in the Average category. The Superscore is an AI-powered score that evaluates a company's overall strength by combining financial performance, product market position, technological capabilities, leadership quality, and relative valuation. It represents the unification of all our scores into a single score for public companies, with five rating bands: Exceptional (90-100), Strong (75-89), Above Average (60-74), Average (40-59), and Cautious (0-39). This score places the company in the Bottom ~21% of all companies we score, or ahead of roughly 21 out of every 100 companies in our database.
Aeluma remains a laboratory experiment waiting for a commercial engine that hasn't started. The Superscore corroborates the bear thesis that stagnant revenue and tripling losses define the current reality more than AI potential does. While its proprietary technology offers a theoretical scale advantage, the immediate financial burn and lack of commercial contracts suggest the business is still fighting to prove its basic viability.